Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study

American Heart Journal

Volumn 158, Issue 2, 2009, Pages

  Pratt, Craig M ^a   Reiffel, James A ^b   Ellenbogen, Kenneth A ^c   Naccarelli, Gerald V ^d   Kowey, Peter R ^e,f  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e Main Line Health Heart Center   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; PLACEBO;

ADULT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LOADING DRUG DOSE; MALE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

EID: 67650567090     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.05.024     Document Type: Article

References (46)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001) 2370-2375
2. Wattigney W.A., Mensah G.A., and Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108 (2003) 711-716
3. Wattigney W.A., Mensah G.A., and Croft J.B. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 155 (2002) 819-826
4. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e257-e354
5. Wolf P.A., Mitchell J.B., Baker C.S., et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158 (1998) 229-234
6. Stewart S., Murphy N., Walker A., et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 90 (2004) 286-292
7. Wu E.Q., Birnbaum H.G., Mareva M., et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 21 (2005) 1693-1699
8. Coyne K.S., Paramore C., Grandy S., et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9 (2006) 348-356
9. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004) 1509-1513
10. Nattel S., and Opie L.H. Controversies in atrial fibrillation. Lancet 367 (2006) 262-272
11. Steinberg J.S., Sadaniantz A., Kron J., et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 109 (2004) 1973-1980
12. Camm J. Medical management of atrial fibrillation: state of the art. J Cardiovasc Electrophysiol 17 suppl 2 (2006) S2-S6
13. Patton K., and Page R. Pharmacological therapy of atrial fibrillation. Expert Opin Invest Drugs 16 (2007) 169-179
14. Nichol G., McAlister F., Pham B., et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 87 (2002) 535-543
15. Waldo A.L. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J 151 (2006) 771-778
16. Dorian P., and Singh B.N. Upstream therapies to prevent atrial fibrillation. European Heart Journal Supplements 10 Supplement H (2008) H11-H31
17. Lovaza package insert. GlaxoSmithKline. Triangle Research Park, NC. 2008.
18. Treatment Guidelines from The Medical Letter. Drugs for lipids (2008), The Medical Letter Inc, New Rochelle, NY 1-16
19. Albert C.M., Hennekens C.H., O'Donnell C.J., et al. Fish consumption and risk of sudden cardiac death. Jama 279 (1998) 23-28
20. Bucher H., Hengstler P., Schindler C., et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112 (2002) 298-304
21. Caló L., Bianconi L., Colivicchi F., et al. n-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized controlled trial. J Am Coll Cardiol 45 (2005) 1723-1728
22. Dhein S., Michaelis B., and Mohr F.W. Antiarrhythmic and electrophysiological effects of long-chain omega-3 polyunsaturated fatty acids. Naunyn Schmiedebergs Arch Pharmacol 371 (2005) 202-211
23. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
24. Leaf A., Albert C., Josephson M., et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acids. Circulation 112 (2005) 2762-2768
25. Mozaffarian D., Psaty B., Rimm E., et al. Fish intake and risk of incident atrial fibrillation. Circulation 110 (2004) 368-373
26. Ninio D, Murphy K, Howe P, Saint D. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. 2005;16:1189-94.
27. Reiffel J., and McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 98 (2006) 50i-60i
28. Xiao Y.F., Sigg D.C., and Leaf A. The antiarrhythmic effect of n-3 polyunsaturated fatty acids: modulation of cardiac ion channels as a potential mechanism. J Membr Biol 206 (2005) 141-154
29. Brouwer I.A., Zock P.L., van Amelsvoort L.G., et al. Association between n-3 fatty acid status in blood and electrocardiographic predictors of arrhythmia risk in healthy volunteers. Am J Cardiol 89 (2002) 629-631
30. Christensen J.H., Korup E., Aaroe J., et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 79 (1997) 1670-1673
31. Sellmayer A., Witzgall H., Lorenz R.L., et al. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 76 (1995) 974-977
32. O'Keefe J.J., Abuissa H., Sastre A., et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 97 (2006) 1127-1130
33. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1223-1230
34. Biscione F., Totteri A., De Vita A., et al. [Effect of omega-3 fatty acids on the prevention of atrial arrhythmias]. Ital Heart J Suppl 6 (2005) 53-59
35. Nodari S., Manerba A., Frattini S., et al. Role of n-3 polyunsaturated fatty acids (n-3 PUFAs) in the prevention of atrial fibrillation relapses (AFR) after electric cardioversion (ECV): one year follow-up. European Heart Journal 29 Abstract supplement (2008) 258
36. Brouwer I., Heeringa J., Geleijnse J., et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 151 (2006) 857-862
37. Frost L. Vestergaard L. n-3 fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 81 (2005) 50-54
38. Erdogan A., Bayer M., Kollath D., et al. Omega AF Study: Polyunsaturated Fatty Acids (PUFA) for Prevention of Atrial Fibrillation Relapse After Successful External Cardioversion. Heart Rhythm 4 Supplement 1 (2007) S185-S186
39. da Cunha D.N., Hamlin R.L., Billman G.E., et al. n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. Br J Pharmacol 150 (2007) 281-285
40. Sakabe M., Shiroshita-Takeshita A., Maguy A., et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 116 (2007) 2101-2109
41. Sarrazin J.F., Comeau G., Daleau P., et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 50 (2007) 1505-1512
42. Pritchett E., Page R., Carlson M., et al. Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 92 (2003) 941-946
43. Meinertz T., Lip G.Y., Lombardi F., et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 90 (2002) 1300-1306
44. Xiao Y.F., Gomez A.M., Morgan J.P., et al. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 94 (1997) 4182-4187
45. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105 (2002) 1897-1903
46. Macchia A., Varini S., Grancelli H., et al. The rationale and design of the FORωARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J 157 (2009) 423-427